Holly H Gallion

Summary

Affiliation: University of Pittsburgh
Country: USA

Publications

  1. ncbi request reprint Randomized phase III trial of standard timed doxorubicin plus cisplatin versus circadian timed doxorubicin plus cisplatin in stage III and IV or recurrent endometrial carcinoma: a Gynecologic Oncology Group Study
    Holly H Gallion
    Division of Gynecologic Oncology, Magee Women s Hospital University of Pittsburgh, Pittsburgh, PA, USA
    J Clin Oncol 21:3808-13. 2003
  2. ncbi request reprint The relationship between histology and outcome in advanced and recurrent endometrial cancer patients participating in first-line chemotherapy trials: a Gynecologic Oncology Group study
    D Scott McMeekin
    Division of Gynecologic Oncology, University of Oklahoma, Oklahoma City, OK 73190, USA
    Gynecol Oncol 106:16-22. 2007
  3. ncbi request reprint Impact of body mass index on treatment outcomes in endometrial cancer patients receiving doxorubicin and cisplatin: a Gynecologic Oncology Group study
    Susan C Modesitt
    Division of Gynecologic Oncology, Department of Obstetrics and Gynecology, University of Virginia, Box 800712, Charlottesville, VA 22908 0712, USA
    Gynecol Oncol 105:59-65. 2007
  4. doi request reprint Does the progression-free interval after primary chemotherapy predict survival after salvage chemotherapy in advanced and recurrent endometrial cancer?: a Gynecologic Oncology Group ancillary data analysis
    Kathleen N Moore
    Division of Gynecologic Oncology, University of Oklahoma, Oklahoma City, Oklahoma 73104, USA
    Cancer 116:5407-14. 2010
  5. ncbi request reprint Racial disparity in survival among patients with advanced/recurrent endometrial adenocarcinoma: a Gynecologic Oncology Group study
    G Larry Maxwell
    Division of Gynecologic Oncology, Department of Obstetrics and Gynecology and the U S Military Cancer Institute, Walter Reed Army Medical Center, Washington, DC, USA
    Cancer 107:2197-205. 2006
  6. ncbi request reprint Expression and activity of taxane-metabolizing enzymes in ovarian tumors
    Julie A DeLoia
    Department of Obstetrics, Gynecology and Reproductive Sciences, University of Pittsburgh, Magee Womens Research Institute, Pittsburgh, PA 15213, USA
    Gynecol Oncol 108:355-60. 2008
  7. ncbi request reprint Percent surface area involvement is a predictor of lymph node metastasis in endometrial cancer
    Allison E Axtell
    Department of Obstetrics, Gynecology and Reproductive Sciences, Division of Gynecologic Oncology, Magee Women s Hospital of University of Pittsburgh Medical Center, 300 Halket Street, Pittsburgh, Pennsylvania 15213, USA
    Gynecol Oncol 107:482-6. 2007
  8. ncbi request reprint Analysis of CHEK2 gene for ovarian cancer susceptibility
    Bora E Baysal
    Department of Obstetrics, Gynecology and Reproductive Sciences, The University of Pittsburgh School of Medicine, Pittsburgh, PA 15260, USA
    Gynecol Oncol 95:62-9. 2004
  9. ncbi request reprint High-resolution methylation analysis of the BRCA1 promoter in ovarian tumors
    Cathy B Wilcox
    Department of Obstetrics, Gynecology and Reproductive Sciences, Magee Womens Research Institute, Lab 420, 204 Craft Avenue, Pittsburgh, PA 15213, USA
    Cancer Genet Cytogenet 159:114-22. 2005
  10. ncbi request reprint Paclitaxel and carboplatin for recurrent or persistent cancer of the cervix
    Anita S Y Sit
    Division of Gynecologic Oncology, Department of Obstetrics and Gynecology, Magee Women s Hospital, Pittsburgh, Pennsylvania, USA
    Cancer Invest 22:368-73. 2004

Detail Information

Publications12

  1. ncbi request reprint Randomized phase III trial of standard timed doxorubicin plus cisplatin versus circadian timed doxorubicin plus cisplatin in stage III and IV or recurrent endometrial carcinoma: a Gynecologic Oncology Group Study
    Holly H Gallion
    Division of Gynecologic Oncology, Magee Women s Hospital University of Pittsburgh, Pittsburgh, PA, USA
    J Clin Oncol 21:3808-13. 2003
    ..To determine if circadian timed (CT) chemotherapy results in improved response, progression-free survival (PFS), overall survival (OS), and lower toxicity, when compared with standard timed (ST) chemotherapy...
  2. ncbi request reprint The relationship between histology and outcome in advanced and recurrent endometrial cancer patients participating in first-line chemotherapy trials: a Gynecologic Oncology Group study
    D Scott McMeekin
    Division of Gynecologic Oncology, University of Oklahoma, Oklahoma City, OK 73190, USA
    Gynecol Oncol 106:16-22. 2007
    ..To explore associations between histology and outcome in advanced or recurrent endometrial cancer patients participating in Gynecologic Oncology Group chemotherapy trials...
  3. ncbi request reprint Impact of body mass index on treatment outcomes in endometrial cancer patients receiving doxorubicin and cisplatin: a Gynecologic Oncology Group study
    Susan C Modesitt
    Division of Gynecologic Oncology, Department of Obstetrics and Gynecology, University of Virginia, Box 800712, Charlottesville, VA 22908 0712, USA
    Gynecol Oncol 105:59-65. 2007
    ..To evaluate the association between body mass index (BMI) and outcomes in women with advanced or recurrent endometrial cancer treated with doxorubicin/cisplatin...
  4. doi request reprint Does the progression-free interval after primary chemotherapy predict survival after salvage chemotherapy in advanced and recurrent endometrial cancer?: a Gynecologic Oncology Group ancillary data analysis
    Kathleen N Moore
    Division of Gynecologic Oncology, University of Oklahoma, Oklahoma City, Oklahoma 73104, USA
    Cancer 116:5407-14. 2010
    ..This study evaluated whether progression-free interval (PFI) following primary chemotherapy (PCT) was predictive of overall survival (OS) after second-line chemotherapy in advanced/recurrent endometrial cancer (EC)...
  5. ncbi request reprint Racial disparity in survival among patients with advanced/recurrent endometrial adenocarcinoma: a Gynecologic Oncology Group study
    G Larry Maxwell
    Division of Gynecologic Oncology, Department of Obstetrics and Gynecology and the U S Military Cancer Institute, Walter Reed Army Medical Center, Washington, DC, USA
    Cancer 107:2197-205. 2006
    ..Previous studies have reported shorter survival of black women compared with white women who had advanced/recurrent endometrial cancer. It has been suggested that this may reflect racially based differences in treatment...
  6. ncbi request reprint Expression and activity of taxane-metabolizing enzymes in ovarian tumors
    Julie A DeLoia
    Department of Obstetrics, Gynecology and Reproductive Sciences, University of Pittsburgh, Magee Womens Research Institute, Pittsburgh, PA 15213, USA
    Gynecol Oncol 108:355-60. 2008
    ..The objective of this study was to determine whether ovarian tumors express genes regulating cellular efflux and subsequent metabolism, and whether any clinico-pathologic features correlated with expression...
  7. ncbi request reprint Percent surface area involvement is a predictor of lymph node metastasis in endometrial cancer
    Allison E Axtell
    Department of Obstetrics, Gynecology and Reproductive Sciences, Division of Gynecologic Oncology, Magee Women s Hospital of University of Pittsburgh Medical Center, 300 Halket Street, Pittsburgh, Pennsylvania 15213, USA
    Gynecol Oncol 107:482-6. 2007
    ..To determine if percent surface area involvement (SAI) of tumor in endometrial cancer is predictive of lymph node metastasis...
  8. ncbi request reprint Analysis of CHEK2 gene for ovarian cancer susceptibility
    Bora E Baysal
    Department of Obstetrics, Gynecology and Reproductive Sciences, The University of Pittsburgh School of Medicine, Pittsburgh, PA 15260, USA
    Gynecol Oncol 95:62-9. 2004
    ..A deletion variant in the CHEK2 gene (del1100C) has been implicated as a low-penetrance risk factor for breast cancer. We sought to determine contribution of CHEK2 mutations to the etiology of ovarian cancer (OvCa)...
  9. ncbi request reprint High-resolution methylation analysis of the BRCA1 promoter in ovarian tumors
    Cathy B Wilcox
    Department of Obstetrics, Gynecology and Reproductive Sciences, Magee Womens Research Institute, Lab 420, 204 Craft Avenue, Pittsburgh, PA 15213, USA
    Cancer Genet Cytogenet 159:114-22. 2005
    ..This finding could be exploited in the design of highly sensitive MS-PCR assays for direct assessment of tumor DNA and potentially for early detection of ovarian cancer in body fluids...
  10. ncbi request reprint Paclitaxel and carboplatin for recurrent or persistent cancer of the cervix
    Anita S Y Sit
    Division of Gynecologic Oncology, Department of Obstetrics and Gynecology, Magee Women s Hospital, Pittsburgh, Pennsylvania, USA
    Cancer Invest 22:368-73. 2004
    ..The objective of this study was to evaluate the effectiveness and degree of toxicity of paclitaxel and carboplatin (PC) combination chemotherapy in patients with recurrent or persistent cervical carcinoma...
  11. ncbi request reprint Feasibility assessment of a chemoresponse assay to predict pathologic response in neoadjuvant chemotherapy for breast cancer patients
    Zhibao Mi
    Precision Therapeutics, Inc, Pittsburgh, PA 15203, USA
    Anticancer Res 28:1733-40. 2008
    ..For chemosensitivity and resistance assays to be clinically useful in predicting patient outcome, they should require small amounts of tissue and be highly reproducible and reliable...
  12. ncbi request reprint Centrosome abnormalities in ovarian cancer
    Lih Ching Hsu
    Department of Obstetrics, Gynecology and Reproductive Sciences, University of Pittsburgh, Magee Womens Research Institute, Pittsburgh, PA 15213, USA
    Int J Cancer 113:746-51. 2005
    ..This is the first demonstration that centrosome abnormalities occur in ovarian tumors. Centrosome dysfunction may be an early event in ovarian carcinogenesis and involved in ovarian tumor progression...